- Home
- GTX vs MLYS Comparison
GTX vs MLYS Comparison
Compare GTX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTX | MLYS |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 2.4B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GTX | MLYS |
|---|---|---|
| Price | $19.13 | $28.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $20.00 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 2.4M | 994.8K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 20.63 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $3,584,000,000.00 | N/A |
| Revenue This Year | $3.99 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | $13.18 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $7.02 | $9.69 |
| 52 Week High | $21.42 | $47.65 |
Technical Indicators
Market Signals| Indicator | GTX | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 40.21 |
| Support Level | $17.41 | $26.85 |
| Resistance Level | $19.28 | $30.05 |
| Average True Range (ATR) | 0.85 | 1.46 |
| MACD | -0.10 | 0.22 |
| Stochastic Oscillator | 38.62 | 32.08 |
Price Performance
Historical ComparisonAbout GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.